Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
|
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [11] Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation
    Norby, Faye L.
    Alonso, Alvaro
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (06) : 549 - 560
  • [12] Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain
    Marti, Edelmira
    Segado, Alejandra
    Pastor-Galan, Irene
    Amat, Paula
    Jose Remigia, Maria
    Solano, Carlos
    Navarro, Blanca
    FUTURE CARDIOLOGY, 2018, 14 (03) : 3 - 8
  • [13] Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem
    Bartlett, Jenna W.
    Renner, Elizabeth
    Mouland, Erin
    Barnes, Geoffrey D.
    Kuo, Liane
    Ha, Nghi B.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (01) : 21 - 27
  • [14] RIVAROXABAN VERSUS WARFARIN IN AFRICAN AMERICAN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Thompson, Stanley
    Ashton, Veronica
    Palladino, Michael
    Bunz, Thomas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 338 - 338
  • [15] Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
    Laube, Eva S.
    Yu, Anthony
    Gupta, Dipti
    Miao, Yimei
    Samedy, Patrick
    Wills, Jonathan
    Harnicar, Stephen
    Soff, Gerald A.
    Mantha, Simon
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (02): : 213 - 217
  • [16] Outcomes With Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation and Worsening Renal Function
    Nakagawara, Jyoji
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Minematsu, Kazuo
    Miyamoto, Susumu
    Murakawa, Yuji
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Ohashi, Yohei
    Sakaguchi, Toshiaki
    Yamamoto, Noriyuki
    Yamanaka, Satoshi
    STROKE, 2019, 50
  • [17] Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation
    Coleman, Craig, I
    Thompson, Stanley
    Ashton, Veronica
    Palladino, Michael
    Bunz, Thomas J.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2020, 112 (04) : 395 - 401
  • [18] ADHERENCE TO RIVAROXABAN AND DABIGATRAN IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES
    Coleman, Craig I.
    Tangirala, Muralikrishna
    Evers, Thomas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 755 - 755
  • [19] Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population
    Fumihiko Kitagawa
    Junnichi Ishii
    Shinya Hiramitsu
    Hiroshi Takahashi
    Ryuunosuke Okuyama
    Hideki Kawai
    Takashi Muramatsu
    Masahide Harada
    Sadako Motoyama
    Hiroyuki Naruse
    Shigeru Matsui
    Masayoshi Sarai
    Mutsuharu Hayashi
    Eiichi Watanabe
    Hideo Izawa
    Yukio Ozaki
    Heart and Vessels, 2017, 32 : 609 - 617
  • [20] Antithrombotic Therapy in Nonvalvular Atrial Fibrillation
    Hochtl, T.
    Huber, K.
    JOURNAL FUR KARDIOLOGIE, 2013, 20 (5-6): : 154 - 159